OLMA Stock Analysis: Olema Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.011m USD | 12M Return: 155.3% | US68062P1066 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.1M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Olema Pharmaceuticals (NASDAQ: OLMA) is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, focused on developing therapies for womens cancers. The companys lead product candidate, palazestrant, is an estrogen receptor (ER) antagonist and selective ER degrader currently being evaluated in the OPERA-01 pivotal Phase 3 trial as a monotherapy for second/third-line ER-positive/HER2-negative metastatic breast cancer, as well as in earlier-stage combination studies with CDK4/6 inhibitors, a PI3Kα inhibitor (alpelisib), and other targeted agents. Olema is also developing OP-3136, an oral KAT6 inhibitor in Phase 1 trials for breast and other solid tumors. The company was originally incorporated in 2006 as CombiThera, Inc., adopting its current name in March 2009, and went public on NASDAQ in November 2020.
As a small-cap clinical-stage biotechnology company with a market capitalization of approximately $862 million, Olema has no approved products and is not yet generating commercial revenue. The biotech business model is characterized by long, capital-intensive development cycles, with revenue typically dependent on eventual regulatory approval and successful market launch of drug candidates. ER-positive/HER2-negative breast cancer represents the largest subtype of breast cancer, making it a commercially significant target area for pharmaceutical developers.
- OPERA-01 Phase 3 palazestrant data is primary stock catalyst
- CDK4/6 and PI3Ka combination trials expand addressable breast cancer market
- R&D burn and cash runway pressure small cap valuation and dilution risk
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.28 > 0.02 and ΔFCF/TA 2.45 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.28 > 3% & CFO -148.7m > Net Income -185.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.8m) vs 12m ago 20.34% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.09%; Δ -0.09% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.88 (Total Current Assets 513.2m - Total Current Liabilities 47.2m) / Total Assets 530.6m |
| B: -1.23 (Retained Earnings -650.6m / Total Assets 530.6m) |
| C: -0.39 (EBIT TTM -185.2m / Avg Total Assets 470.1m) |
| D: 9.58 (Book Value of Equity 480.5m / Total Liabilities 50.2m) |
| Altman-Z'' = 9.17 = AAA |
As of August 09, 2026, the stock is trading at USD 12.05 with a total of 748,140 shares traded. Over the past week, the price has changed by +5.24%, over one month by -4.59%, over three months by -20.36% and over the past year by +155.30%.
Current recommended Stop Loss: 10.30 (which is 14.5% or 2.5 ATR below the current price).
Olema Pharmaceuticals has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy OLMA.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 40.7 | 237.8% |
P/B = 2.0815
Revenue TTM = 0.0 USD
EBIT TTM = -185.2m USD
EBITDA TTM = -184.7m USD
Long Term Debt = 3.00m USD (from longTermDebt, last quarter)
Short Term Debt = 956k USD (from shortTermDebt, last quarter)
Debt = 4.91m USD (corrected: LT Debt 3.00m + ST Debt 956k) + Leases 956k
Net Debt = -500.4m USD (calculated: Debt 4.91m - CCE 505.3m)
Enterprise Value = 511.0m USD (1.01b + Debt 4.91m - CCE 505.3m)
Interest Coverage Ratio = unknown (Ebit TTM -185.2m / Interest Expense TTM 0.0)
EV/FCF = -3.44x (Enterprise Value 511.0m / FCF TTM -148.7m)
FCF Yield = -29.10% (FCF TTM -148.7m / Enterprise Value 511.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 0.96 (Enterprise Value 511.0m / Total Assets 530.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 4.91m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -146.3m (EBIT -185.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.88 (Total Current Assets 513.2m / Total Current Liabilities 47.2m)
Debt / Equity = 0.01 (Debt 4.91m / totalStockholderEquity, last quarter 480.5m)
Debt / EBITDA = 2.71 (negative EBITDA) (Net Debt -500.4m / EBITDA -184.7m)
Debt / FCF = 3.36 (negative FCF - burning cash) (Net Debt -500.4m / FCF TTM -148.7m)
Total Stockholder Equity = 402.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.38% (Net Income -185.2m / Total Assets 530.6m)
RoE = -45.95% (Net Income TTM -185.2m / Total Stockholder Equity 402.9m)
RoCE = -45.61% (EBIT -185.2m / Capital Employed (Equity 402.9m + L.T.Debt 3.00m))
RoIC = -30.19% (negative operating profit) (NOPAT -146.3m / Invested Capital 484.4m)
WACC = 5.59% (E(1.01b)/V(1.02b) * Re(5.62%) + D(4.91m)/V(1.02b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 5.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.63 | Cagr: 32.28%
[DCF] Fair Price = unknown (Cash Flow -148.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.08 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.56 | Chg30d=-0.52% | Revisions=+0% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.58 | Chg30d=-1.14% | Revisions=+18% | Analysts=9
EPS current Year (2026-12-31): EPS=-2.27 | Chg30d=-1.10% | Revisions=-8% | GrowthEPS=-21.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.48 | Chg30d=-7.08% | Revisions=+0% | GrowthEPS=-9.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +3% (up=17, down=16)